$JAZZ · Jazz Pharmaceuticals plc
Jazz Pharmaceuticals reported Q3 2026 total revenues of $1.243B (+10% YoY), raised full-year 2026 revenue guidance to $4.775B–$4.85B, and posted a GAAP net loss of $483.4M (-$7.48/share) driven by a $754M acquired IPR&D charge from the Actio acquisition. Non-GAAP adjusted net loss was $250.8M (-$3.88/share). Key growth drivers included Xywav at $483M (+12%), Zepzelca at $104M (+32%), and the Ziihera 1L GEA launch. The company also completed a $1.25B exchangeable notes offering, repurchased $225M in shares, and authorized a new $500M buyback program.
- Total revenues of $1.243B in Q3 2026, up 10% YoY from $1.126B, driven by Xywav (+12%), Zepzelca (+32%), and Modeyso.
- GAAP net loss of $483.4M (-$7.48/share) vs. net income of $251.4M (+$4.08/share) in Q3 2025, due to a $754M acquired IPR&D charge from the Actio acquisition.
- Non-GAAP adjusted net loss of $250.8M (-$3.88/share); the Actio IPR&D charge impacted non-GAAP EPS by $11.03 per share.
- Full-year 2026 total revenue guidance raised to $4.775B–$4.85B; company also approved a new $500M share repurchase program.
- Ziihera launched in 1L HER2+ GEA following August 2026 FDA approval; early demand up ~40% in average daily vials with threefold increase in new ordering accounts.
Extended-hours trading shows shares at $216.94, up +1.17% vs the regular close of $214.44, suggesting the market is rewarding the revenue beat and guidance raise while looking through the non-cash IPR&D charge. The $13.92B market cap provides ample liquidity to absorb the $754M accounting hit.
A rare combination: double-digit revenue growth and raised guidance alongside a massive GAAP loss — the $754M IPR&D charge masks underlying commercial momentum across sleep, epilepsy, and oncology.
Jazz's oncology franchise grew 34% YoY to $387M in Q3, with Ziihera's 1L GEA launch and Zepzelca's 32% growth offsetting legacy declines. The Actio deal mirrors the sector trend of bolt-on rare-disease acquisitions to backfill pipelines ahead of Xywav's eventual LOE.
The $754M acquired IPR&D charge for ABS-1230 (JZP6979) from the Actio acquisition reflects significant capital at risk on an early-stage KCNT1 epilepsy asset still in Phase 1b/2a. Epidiolex revenue declined 2% YoY to $295M, pressured by wholesaler buying patterns and unfavorable gross-to-net comparisons.